Lv4
572 积分 2023-07-25 加入
P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
22天前
已关闭
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
22天前
已完结
Tulisokibart shows promise for Crohn's disease
22天前
已关闭
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
1个月前
已完结
IL-23 in inflammatory bowel diseases and colon cancer
1个月前
已完结
P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
1个月前
已完结
Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety
1个月前
已完结
Cryo-EM structure of the TL1A-DR3 complex and implications for the treatment of Inflammatory Bowel Disease
1个月前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
1个月前
已完结
Molecular bioengineering of functional nucleic acids
6个月前
已完结
皖公网安备34019202002308
